New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - anastrozole 1mg;   - film coated tablet - 1 mg - active: anastrozole 1mg   excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 16mg;  ;   - tablet - 16 mg - active: candesartan cilexetil 16mg     excipient: carmellose calcium ferrous oxide hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch purified water - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 32mg;  ;   - tablet - 32 mg - active: candesartan cilexetil 32mg     excipient: carmellose calcium ferrous oxide hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 4mg;  ;   - tablet - 4 mg - active: candesartan cilexetil 4mg     excipient: carmellose calcium hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch purified water - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 8mg;  ;   - tablet - 8 mg - active: candesartan cilexetil 8mg     excipient: carmellose calcium ferrous oxide hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch purified water - treatment of hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 90mg;  ;  ;   - film coated tablet - 90 mg - active: ticagrelor 90mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide yellow macrogol 400 magnesium stearate mannitol purified talc purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 10µg/40µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 5µg/20µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.